Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Novan, Inc. (NOVN)

0.8321   0.008 (0.96%) 11-28 11:01
Open: 0.8333 Pre. Close: 0.8242
High: 0.8333 Low: 0.81
Volume: 46,545 Market Cap: 20(M)

Technical analysis

as of: 2022-11-28 10:50:58 AM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.29     One year: 1.53
Support: Support1: 0.79    Support2: 0.65
Resistance: Resistance1: 1.11    Resistance2: 1.3
Pivot: 0.93
Moving Average: MA(5): 0.83     MA(20): 0.98
MA(100): 1.96     MA(250): 2.78
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 8.4     %D(3): 8.9
RSI: RSI(14): 27.9
52-week: High: 5.07  Low: 0.79
Average Vol(K): 3-Month: 187 (K)  10-Days: 234 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NOVN ] has closed above bottom band by 29.3%. Bollinger Bands are 20.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.86 - 0.87 0.87 - 0.87
Low: 0.79 - 0.8 0.8 - 0.8
Close: 0.81 - 0.82 0.82 - 0.83

Company Description

Novan, Inc., a medical dermatology company, focuses on researching, developing, and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Headline News

Sat, 26 Nov 2022
Novartis AG's (VTX:NOVN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance

Tue, 22 Nov 2022
Generic drugmakers Teva and Sandoz make major push to biosimilars - Reuters

Mon, 21 Nov 2022
Teva hires ex-Novartis executive to succeed CEO Schultz - Reuters

Thu, 17 Nov 2022
NOVN: 3Q:22 Results - Yahoo Finance

Thu, 17 Nov 2022
Novartis AG's (VTX:NOVN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? - Simply Wall St

Wed, 16 Nov 2022
Novartis Weighs Ophthalmology, Respiratory Unit Sales (SWX:NOVN) - Bloomberg

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 24 (M)
Shares Float 22 (M)
% Held by Insiders 4.5 (%)
% Held by Institutions 18.8 (%)
Shares Short 558 (K)
Shares Short P.Month 586 (K)

Stock Financials

EPS -1.9
EPS Est Next Qtl -0.57
EPS Est This Year -2.49
EPS Est Next Year -3.6
Book Value (p.s.) 0.28
Profit Margin (%) -263.6
Operating Margin (%) -286.4
Return on Assets (ttm) -31.6
Return on Equity (ttm) -221.8
Qtrly Rev. Growth 594
Gross Profit (p.s.) -0.73
Sales Per Share 0.56
EBITDA (p.s.) -1.54
Qtrly Earnings Growth 0
Operating Cash Flow -29 (M)
Levered Free Cash Flow -26 (M)

Stock Valuations

PE Ratio -0.44
PEG Ratio 0
Price to Book value 2.97
Price to Sales 1.46
Price to Cash Flow -0.72

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.